DOCSLIB.ORG

Appendix A: Medications Used in the Treatment of Inborn Errors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Appendix A: Medications Used in the Treatment of Inborn Errors Appendix A: Medications Used in the Treatment of Inborn Errors JH Walter and JE Wraith J.-M. Saudubray et. al (Eds.), Inborn Metabolic Diseases, DOI 10.1007/978-3-642-15720-2, © Springer- Verlag Berlin Heidelberg 2012 626 Appendix A · Medications Used in the Treatment of Inborn Errors Medication Mode of action Disorders Recommended dose Route Remarks Chapters Agalsidase Recombinant analogue of Fabry disease 0.2 mg/kg alt weeks IV 40 alfa (Repla- human α-galactosidase gal) A manufactured by gene activation in human fibro- blast cell line Agalsidase Recombinant analogue of Fabry disease 1.0 mg/kg alt weeks IV 40 beta (Fabra- human α-galactosidase A zyme) manufactured in Chinese Hamster Ovary (CHO) cell line Aglucosi- Recombinant analogue Pompe disease 20 mg/kg alt weeks IV 6 dase alfa of human α-glucosidase (Myozyme®) manufactured in Chinese Hamster Ovary (CHO) cell line AllopurinolXanthine-oxidase inhibitor Disorders leading Initial dosage 10-20 Oral36 to hyperuricaemia mg/kg per day in chil- (PRPP synthetase dren and 2-10 mg/kg superactivity; HGPRT per day in adults deficiency) and APRT deficiency Ammonium Chelating agent Wilson’s disease 160 mg/d in 6 divided Oral38 tetrathiomo- doses lybdate Betaine Remethylates hct to meth Classic homocysti- 100-150 mg/kg/day in Oral21 nuria two to three divided Remethylation de- doses, max. dose 6-9 fects g/d Biotin Co-factor for carboxylases Biotinidase defi- 5-20 mg/d Oral or 27 Treatment of presumed ciency, IV 2 transporter defect Multiple carboxylase deficiency Biotin-responsive basal ganglia disease Chenode- Inhibits cholesterol 7a- 3β-Dehydrogenase 3β-D: 12-18 mg/kg/d Oral34 oxycholic hydroxylase (rate-limiting def (3β-D); for first 2 months then acid enzyme in bile acid biosyn- Δ4-3-Oxosteroid 5β- 9-12 mg/kg/d; 3-ORD thesis) reductase deficiency :8 mg/kg/day; CTX: 750 (3-ORD); Cerebroten- mg/day (adults) dinous xanthomato- sis (CTX) CholesterolReplenishes cholesterolSmith-Lemli-Opitz 20-40 mg/kg/d in 3-4 Oral33 (SLO) syndrome divided doses Cholesty- Bile acid sequestrant Familial hypercholes- Adults: 12-24 g /d OralPossible 32 ramine terolaemia children: (wt in kg/70 vitamin A, D, x adult dose ) in four and K defi- divided doses ciency with prolonged treatment. Other bile acid resins include colestipol & colesevalam 627 Appendix A · Medications Used in the Treatment of Inborn Errors Medication Mode of action Disorders Recommended dose Route Remarks Chapters Cholic acidΔ4-3-Oxosteroid 5β- 8 mg/kg/day Oral33 reductase deficiency (3-ORD) Copper Increases intracellular Menkes disease 100-200 μg Cu/d (new- SC 38 histidine copper born) 1 mg Cu/d in older children Creatine Replenishes creatine Guanidinoacetate 300-400 mg/kg/d in Oral16 monohy- methyltransferase three to six divided drate (GAMT) deficiency doses arginine:glycine amidinotransferase (AGAT) deficiency Cyclic pyra- Replenishes deficient prod- Molybdenum co- 80-160 mg/kg/d IV 36 nopterin uct to allow production of factor deficiency monophos- molybdenum co-factor type A phate (cPMP) Cysteamine/ Depletes lysosomal cystine Cystinosis 1.3 g/m2/day of free- Oral Phospho- 43 phospho- base), given every 6 h and eye cysteamine cysteamine drops more palat- able Dextro- NMDA channel antagonist NKH 5-7 mg/kg/d in four Oral Doses up to 24 methorphan divided doses 35/mg/d have been used Diazoxide Inhibits insulin secretion Persistent hyperinsu- 15 mg/kg/d (newborn); Oral10 linism 10 mg/kg/d (infants), in three divided doses Dichloroac- Stimulates PDH activity by Primary lactic aci- 50 mg/kg/d in 3-4 di- Oral May cause 12 etate inhibiting PDH kinase dosis vided doses polyneurop- athy with prolonged use Entacapone Prevents the peripheral Disorders of BH4 15mg/kg/d in two to Oral17 breakdown of l-dopa synthesis three divided doses Ezetimibe Inhibits cholesterol absorp- Familial hypercholes- 10 mg/d Oral32 tion terolaemia Folinic acidProvides accessible source DHPR deficiency, 5-15 mg/d Oral, IV 17, 28 of folate for CNS UMP synthase defi- ciency (hereditary orotic aciduria), Methylene synthase deficiency, Methionine synthase deficiency, Hereditary folate ma- labsorption, Some disorders of cobalamin metabo- lism, Cerebral folate trans- porter 628 Appendix A · Medications Used in the Treatment of Inborn Errors Medication Mode of action Disorders Recommended dose Route Remarks Chapters Galsulfase Recombinant analogue Mucopolysacchari- 1.0 mg/kg per weekIV 40 (Naglazyme) of human N-acetylga- dosis type VI lactosamine 4 sulfatase manufactured in Chinese Hamster Ovary (CHO) cell line GemfibrozilFibrates decrease TG levels; Mixed or combined Adult dose: 1.2 g daily, OralCan cause a 32 other fibrates include beza- hyperlipidaemia usually in two divided myositis-like fibrate and fenofibrate doses; range 0.9–1.5 g syndrome, daily especially with impaired renal function; combination with a statin increases risk of rhabdomy- olysis G-CSF Stimulates granulocyte Neutropenia in GSD 5 μg/kg once daily SC 6 production Ib, Ic Glycine Forms isovalerylglycine Isovaleric acidaemia 150 mg/kg/d in three OralUp to 600 mg/ 19 with high renal clearance divided doses kg/d during decompensa- tion Haem Inhibits 5-aminolevulinic Acute porphyrias 3-4 mg/kg once daily IV 37 arginate acid synthase for 4 days Hydroxoco- Co-factor for methylmalo- Disorders of cobala- 1 mg IM daily; oral IM or Dose may 19, 28 balamin nyl mutase min metabolism dose 10 mg once or oral be reduced (vitamin B12) twice daily to once or twice weekly according to response 5-Hydroxy- Neurotransmitter replace- Disorders of neu- 1-2 mg/kg, increasing Oral Monitor CSF 17,29 tryptophan ment rotransmitter syn- gradually to 8-10 mg/ 5HIAA levels thesis kg in 4 divided doses Idursulfase Recombinant iduronate- MPS II 0.5 mg per kg by IV IV 40 (Elaprase®) 2-sulfatase produced in infusion weekly human cell line Imiglucerase Recombinant Gaucher disease Various regimens: IV 40 (Cerezyme) analogue of human 2.5 U/kg 3X per week β-glucocerebrosidase to manufactured in Chinese 60 U/kg per 2 weeks Hamster Ovary (CHO) line For type III Gaucher disease some clinicians recommend higher dosages: 120 U/kg per 2 weeks Ketamine N-Methyl-d-aspartate NKH 1-30 mg/kg/d in four Oral or 24 (NDMA) channel antago- divided doses IV nist l–Arginine Replenishes arginine; sub- Urea cycle disorders; 50-170 mg/kg (OCT Oral or IV loading 20 strate of nitrous oxide MELAS and CPS def) IV dose: (200 Up to 700 mg/kg in AL mg/kg) over & AS def 90 min 629 Appendix A · Medications Used in the Treatment of Inborn Errors Medication Mode of action Disorders Recommended dose Route Remarks Chapters Laronidase Recombinant ana- Mucopolysacchari- 100 U/kg per weekIV 40 (Aldura- logue of human α-l- dosis type I zyme) iduronidase manufac- tured in Chinese Ham- ster Ovary (CHO) line l-Carnitine Replenishes body stores; Primary and second- 100-200 mg/kg/d Oral or Do not use ra- 13, 19, ,23 Removes toxic acyl-CoA ary carnitine defi- IV cemix mixture intermediates from within ciencies the mitochondria l-Citrulline Replenishes citrulline and Used as an alterna- CPS & OCT def: 170 Oral 20, 26 arginine tive to arginine in mg/kg/day or 3.8 gm/ CPS def and OCT m2/day in divided dos- def; LPI es, LPI: 100 mg/kg/d in 3-5 doses l-Dopa Replacement of neu- Disorders of l-dopa 1-2 mg/kg increasing OralGive as l-do- 17,29 rotransmitters synthesis slowly to 10-12 mg/kg pa/carbidopa in four divided doses (1:10 or 1:5) Monitor CSF HVA levels l-Lysine-HCl Allows lysine absorption Lysinuric protein 20-30 mg/kg/day in Oral26 Intolerance three divided doses l-Serine Replenishes serine 3-Phosphoglycerate up to 600 mg/d in sic Oral25 dehydrogenase de- divided doses ficiency l-Tryptophan Increases kynurenic acid NKH 100 mg/kg/d in three Oral24 which is an endogenous divided doses antagonist of the NMDA receptor Magnesium Replenishes Mg Primary hypomagne- 0.5-1.5 ml/kg/d MgSO4 IV / oral38 saemia with second- 10% solution IV; oral ary hypocalcaemia maintenance 0.7-3.5 mmol/kg/d elemental Mg in three to five di- vided doses Mannose Improves glycosylation CDG Ib (PMI defi- 1 g /kg/d in five di- Oral Not of benefit 42 ciency) vided doses in CDG Ia Mercap- Chelating agent Cystinuria 15-20 mg/kg/d, up to Oral 26 topropio- max of 1,000 mg/d in nylglycine three divided doses (tiopronin) Metranida- Reduces propionate pro- Propionic and meth- 7.5-20 mg/kg once Oral19 zole duction by gut bacteria ylmalonic acidaemia daily Miglustat Inhibitor of glucosylcer- Gaucher disease; 100 mg TDSOralOnly recom- 39, 40 (Zavesca) amide synthase, the first neurological mani- mended for enzyme responsible for festations of NPC patients with glycosphingolipid (GSL) mild to mod- synthesis erate Gaucher disease who are unsuitable for enzyme replacement therapy. 630 Appendix A · Medications Used in the Treatment of Inborn Errors Medication Mode of action Disorders Recommended dose Route Remarks Chapters N-Carbam- Stimulates N-acetylgluta- N-Acetylglutamate 100-300 mg/kg/day in Oral 19, 20 oylgluta- mate synthase synthase deficiency, four divided doses mate Carbamoylphos- phate synthase defi- ciency Hyperammonaemia associated with or- ganic acidaemias Nicotin- Replenishes deficiency Hartnup disease 50-300 mg/day Oral26 amide state Nicotinic Inhibits the release of free Hyperlipidaemia (see Adult dose: 100– Oral32 acid (niacin) fatty acids from adipose Chapter 32 for indica- 200 mg 3 times daily, tissue; increases HDL- tions) gradually increased cholesterol over 2–4 weeks to 1–2 g three times daily NTBC (2-[2- Inhibits 4-hydroxyphe- Tyrosinaemia type I1 mg/kg in one to two OralCombine with 18 nitro-4-triflu- nylpyruvate
Load more

Recommended publications
  • Second-Tier DNA Confirmation of Newborn Screening Results
    Second-tier DNA Confirmation of Newborn Screening by Targeted Next Generation Sequencing Edwin Naylor, Ph.D. MPH Andy Bhattacharjee , Ph.D. Erik Puffenberger, Ph.D.; Kevin Strauss, MD; Holmes Morton, MD Newborn Screening & Clinical Genomics 1961 1990’s 2010-2012 2 Robert Guthrie Development of develops simple automated MS/MS Newborn Screening screening across (NBS) several disorders Current de facto standard 2 Why Newborn Genomics? • Mendelian Diseases disproportionately affect Newborns - ~3500 genetic diseases with molecular basis - >10% of NICU admissions are genetic Clinical manifestation of Genetic diseases - Current NBS tests limited to 29+ diseases CHROMOSOMAL - 2nd tier DNA testing to validate biochemical results MULTI-FACTORIAL SINGLE GENE (MENDELIAN) • Advantage of NGS based DNA testing individuals # of Affected - Find causal variants (rare/novel) in gene(s) - A ‘universal’ NGS approach avoids repeated, serial BIRTH PUBERTY ADULT single gene testing Gelehrter TD, Collins FS, Ginsburg D. Principles of - Current Sanger sequencing is expensive ($3-10K) and Medical Genetics. 2nd ed. Baltimore, MD: Williams & slow (3 months to 1 year) Wilkins; 1998:1-42 NICU- Neonatal Intensive Care Unit NBS-Newborn Screening 3 NGS-Next Generation Sequencing Why Targeted (Exome) Sequencing for now? NGS Sequencing * Genomic DNA from Causal Mutations in Affected Individuals Exons/Target Regions Fold Test Menu Cost ($) Throughput Efficiency Whole Genome (Res.) 7,666* 1 1 Exome (Res) 1,200 15 95 Neonate Panel (Clinical) <1000 150 >1140 •Majority of known disease-causing mutations in exons •Exome = protein-encoding parts of genes •Targeted NGS is Cost & Throughput Efficient *Saunders et al., (2012) Rapid Whole Genome Sequencing for Genetic Disease Diagnosis in NICUs 4 Workflow for 2nd Tier Newborn Screening Sample 2h DNA Capture 92h Raw Data 10h Analysis 1h+ Isolation & Sequencing Management & Interpretation 8 samples, 105 Hrs, <$10,000 = Real Neonatal Genomics! 5 Workflow for 2nd Tier Newborn Screening Sample •High M.Wt.
    [Show full text]
  • Newborn Screening Laboratory Manual of Services
    Newborn Screening Laboratory Manual of Services Test Panel: Please see the following links for a detailed description of testing in the Newborn Screening section. Information about the Newborn Screening program is available here. Endocrine Disorders Congenital adrenal hyperplasia (CAH) Congenital hypothyroidism (TSH) Hemoglobinopathies Sickle cell disease (FS) Alpha (Barts) Sickle βeta Thalassemia (FSA) Other sickling hemoglobinopathies such as: FAS FAC FAD FAE Homozygous conditions such as: FC FD FE Metabolic Disorders Biotinidase deficiency Galactosemia Cystic fibrosis (CF) first tier screening for elevated immunoreactive trypsinogen (IRT) Cystic fibrosis second tier genetic mutation analysis on the top 4% IRT concentrations. Current alleles detected : F508del, I507del, G542X, G85E, R117H, 621+1G->T, 711+1G->T, R334W, R347P, A455E, 1717-1G->A, R560T, R553X, G551D, 1898+1G->A, 2184delA, 2789+5G->A, 3120+1G->A, R1162X, 3659delC, 3849+10kbC->T, W1282X, N1303K, IVS polyT T5/T7/T9 *Currently validating a mutation panel that includes the above alleles in addition to the following: 1078delT, Y122X, 394delTT, R347H, M1101K, S1255X, 1898+5G->T, 2183AA->G, 2307insA, Y1092X, 3876delA, 3905insT, S549N, S549R_1645A->C, S549R-1647T->G, S549R-1647T->G, V520F, A559T, 1677delTA, 2055del9->A, 2143delT, 3199del6, 406-1G->A, 935delA, D1152H, CFTRdele2, E60X, G178R, G330X, K710X, L206W, Q493X, Q890X, R1066C, R1158X, R75X, S1196X, W1089X, G1244E, G1349D, G551S, R560KT, S1251N, S1255P Amino acid disorders Phenylketonuria (PKU) / Hyperphenylalaninemia Maple
    [Show full text]
  • Pharmacy Prior Authorization Non-Formulary and Prior
    Pharmacy Prior Authorization Non-Formulary and Prior Authorization Guidelines Scroll down to see PA Criteria by drug class, or Ctrl+F to search document by drug name PA Guideline Requirements Duration of Approval if Requirements Are Met Non-Formulary Requests for Non-Formulary Medications that do not have specific Prior Authorization Initial Approval: Medication Guidelines will be reviewed based on the following: • Minimum of 3 months, Guideline • An appropriate diagnosis/indication for the requested medication, depending on the • An appropriate dose of medication based on age and indication, diagnosis, to determine • Documented trial of 2 formulary agents for an adequate duration have not been effective or adherence, efficacy and tolerated patient safety monitoring OR • All other formulary medications are contraindicated based on the patient’s diagnosis, other Renewal: medical conditions or other medication therapy, • Minimum of 6 months OR • Maintenance medications • There are no other medications available on the formulary to treat the patient’s condition may be approved Indefinite Maryland Physicians Care determines patient medication trials and adherence by a review of pharmacy claims data over the preceding twelve months. Additional information may be requested on a case-by-case basis to allow for proper review. Medications Requests for Medications requiring Prior Authorization (PA) will be reviewed based on the PA As documented in the requiring Prior Guidelines/Criteria for that medication. Scroll down to view the PA Guidelines for specific individual guideline Authorization medications. Medications that do not have a specific PA guideline will follow the Non-Formulary Medication Guideline. Additional information may be required on a case-by-case basis to allow for adequate review.
    [Show full text]
  • Gentaur Products List
    Chapter 2 : Gentaur Products List • Rabbit Anti LAMR1 Polyclonal Antibody Cy5 Conjugated Conjugated • Rabbit Anti Podoplanin gp36 Polyclonal Antibody Cy5 • Rabbit Anti LAMR1 CT Polyclonal Antibody Cy5 • Rabbit Anti phospho NFKB p65 Ser536 Polyclonal Conjugated Conjugated Antibody Cy5 Conjugated • Rabbit Anti CHRNA7 Polyclonal Antibody Cy5 Conjugated • Rat Anti IAA Monoclonal Antibody Cy5 Conjugated • Rabbit Anti EV71 VP1 CT Polyclonal Antibody Cy5 • Rabbit Anti Connexin 40 Polyclonal Antibody Cy5 • Rabbit Anti IAA Indole 3 Acetic Acid Polyclonal Antibody Conjugated Conjugated Cy5 Conjugated • Rabbit Anti LHR CGR Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Integrin beta 7 Polyclonal Antibody Cy5 • Rabbit Anti Natrexone Polyclonal Antibody Cy5 Conjugated • Rabbit Anti MMP 20 Polyclonal Antibody Cy5 Conjugated Conjugated • Rabbit Anti Melamine Polyclonal Antibody Cy5 Conjugated • Rabbit Anti BCHE NT Polyclonal Antibody Cy5 Conjugated • Rabbit Anti NAP1 NAP1L1 Polyclonal Antibody Cy5 • Rabbit Anti Acetyl p53 K382 Polyclonal Antibody Cy5 • Rabbit Anti BCHE CT Polyclonal Antibody Cy5 Conjugated Conjugated Conjugated • Rabbit Anti HPV16 E6 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti CCP Polyclonal Antibody Cy5 Conjugated • Rabbit Anti JAK2 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti HPV18 E6 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti HDC Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Microsporidia protien Polyclonal Antibody Cy5 • Rabbit Anti HPV16 E7 Polyclonal Antibody Cy5 Conjugated • Rabbit Anti Neurocan Polyclonal
    [Show full text]
  • Inherited Metabolic Disease
    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
    [Show full text]
  • Regulation of Skeletal Muscle Glucose Transport and Glucose Metabolism by Exercise Training
    nutrients Review Regulation of Skeletal Muscle Glucose Transport and Glucose Metabolism by Exercise Training Parker L. Evans 1,2,3, Shawna L. McMillin 1,2,3 , Luke A. Weyrauch 1,2,3 and Carol A. Witczak 1,2,3,4,* 1 Department of Kinesiology, East Carolina University, Greenville, NC 27858, USA; [email protected] (P.L.E.); [email protected] (S.L.M.); [email protected] (L.A.W.) 2 Department of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA 3 East Carolina Diabetes & Obesity Institute, East Carolina University, Greenville, NC 27834, USA 4 Department of Biochemistry & Molecular Biology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA * Correspondence: [email protected]; Tel.: +1-252-744-1224 Received: 8 September 2019; Accepted: 8 October 2019; Published: 12 October 2019 Abstract: Aerobic exercise training and resistance exercise training are both well-known for their ability to improve human health; especially in individuals with type 2 diabetes. However, there are critical differences between these two main forms of exercise training and the adaptations that they induce in the body that may account for their beneficial effects. This article reviews the literature and highlights key gaps in our current understanding of the effects of aerobic and resistance exercise training on the regulation of systemic glucose homeostasis, skeletal muscle glucose transport and skeletal muscle glucose metabolism. Keywords: aerobic exercise; blood glucose; functional overload; GLUT; hexokinase; insulin resistance; resistance exercise; SGLT; type 2 diabetes; weightlifting 1. Introduction Exercise training is defined as planned bouts of physical activity which repeatedly occur over a duration of time lasting from weeks to years.
    [Show full text]
  • Early Modifications of Gene Expression Induced in Liver by Azo-Dye Diet
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 206, number 2 FEBS 4070 October 1986 Early modifications of gene expression induced in liver by azo-dye diet EugCnia Lamas, Fabien Schweighoffer and Axe1 Kahn Unit& de Recherches en GP&tique et Pathologie Mol&ulaires, INSERM U 129, CHU COCHIN, 24, Rue du Faubourg Saint Jacques, 75674 Paris Cedex 14, France Received 5 August 1986 The expression and regulation of the phosphoenolpyruvate carboxykinase gene were not grossly modified by feeding rats a 3’-methyl-4-(dimethylamino)azobenzene-containing diet despite maximum expression of the L-type pyruvate kinase gene being dramatically reduced as early as the 24th hour of the carcinogenic diet. Inhibition of aldolase B mRNA synthesis occurred more slowly, being maximum at the 3rd day. After stopping administration of the carcinogen, a very rapid, but transient increase of the L-type pyruvate kinase mRNA was observed at the 24th hour, whereas aldolase B mRNA increased only slowly. The amount of aldolase A mRNA fell quickly after termination of carcinogen administration, levels being normal at the 2nd-3rd day. At this time, the histological structure of the liver was indistinguishable from that of animals still receiving the azo-dye diet. It appears, therefore, that in the rat both administration and withdrawal of the azo-dye carcinogen induce rapid modifications of the expression of some genes, before any cellular modification is distinguishable. Azo-dye diet mRNA Hepatocarcinogenesis Phosphoenolpyruvate carboxykinase Aldolase Pyruvate kinase 1. INTRODUCTION some genes. Such a possibility is of theoretical im- portance because it could constitute the basis for The azo-dye 3’-methyl-4-(dimethylamino)azo- the carcinogenic action of the dye.
    [Show full text]
  • Glutaric Acidemia Type 1
    Glutaric acidemia type 1 What is glutaric acidemia type 1? Glutaric acidemia type 1 is an inherited disease characterized by episodes of severe brain dysfunction that result in spasticity, low muscle tone, and seizures.1,2 Individuals with glutaric acidemia type 1 have defects in the glutaryl-CoA dehydrogenase enzyme, which breaks down the amino acids lysine, hydroxylysine, and tryptophan. The symptoms of glutaric acidemia type 1 are due to the build-up of these amino acids and their metabolites in the body, primarily affecting the brain.1 Glutaric acidemia type 1 is also known as glutaric aciduria type 1.2 What are the symptoms of glutaric acidemia type 1 and what treatment is available? The severity of symptoms of glutaric acidemia type 1 can vary widely, even within families. Newborns may have macrocephaly (large head size) with no other signs or symptoms. Symptoms typically begin within months after birth and are often triggered by illness or fasting. Symptoms may include2: • Hypotonia (low muscle tone) • Feeding difficulties • Poor growth • Swelling of the brain • Spasticity (abnormally tight muscles) • Dystonia (sustained muscle contractions causing twisting movements and abnormal posture) • Seizures • Developmental delays • Coma, and possibly death, especially if untreated Individuals tend to have a reduced life expectancy. Approximately 10% of individuals die within the first decade; more than half do not survive past 35 years of age. 3 There is no cure for glutaric acidemia type 1, and treatment is aimed at preventing episodes of brain dysfunction and seizures. Treatment generally includes a low protein diet and nutrition supplements, and a feeding tube may be required for some individuals.
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Fructose in Medicine Jussi K. HUTTUNEN
    Postgrad Med J: first published as 10.1136/pgmj.47.552.654 on 1 October 1971. Downloaded from Poitgraduate Medical Journal (October 1971) 47, 654-659. CURRENT SURVEY Fructose in medicine A review with particular reference to diabetes mellitus Jussi K. HUTTUNEN M.D. Third Department of Medicine, University of Helsinki, Finland Summary and in experimental animals. Earlier suggestions con- A review is given of the metabolism of fructose in the cerned with the atherogenic properties of fructose mammalian organism, and its significance in medicine. have recently been challenged. The apparent increase Emphasis is laid upon the absorption and assimilation in the incidence of coronary disease among sucrose of fructose through pathways not identical with those users seems to be a statistical artefact, caused by the of glucose. The metabolism of fructose is largely increased ingestion of coffee and soft drinks by insulin-independent, although the ultimate fate of cigarette smokers. fructose carbons is determined by the presence or the absence of insulin. Introduction Clinical and experimental work has suggested that The metabolism of fructose has engaged the atten- fructose may exert beneficial effects as a component tion of clinicians since 1874, when Kulz suggestedProtected by copyright. of the diet for patients with mild and well-balanced that diabetic patients can assimilate fructose better diabetes. Fructose is absorbed slowly from the gut, than glucose. These observations have been con- and does not induce drastic changes in blood sugar firmed in a number of experimental and clinical levels. Secondly, fructose is metabolized by insulin- studies (Minkowski, 1893; Naunyn, 1906; Joslin, independent pathways in the liver, intestinal wall, 1923), it being further shown that in some patients kidney and adipose tissue.
    [Show full text]
  • Fructose and Mannose in Inborn Errors of Metabolism and Cancer
    H OH metabolites OH Review Fructose and Mannose in Inborn Errors of Metabolism and Cancer Elizabeth L. Lieu †, Neil Kelekar †, Pratibha Bhalla † and Jiyeon Kim * Department of Biochemistry and Molecular Genetics, University of Illinois, Chicago, IL 60607, USA; [email protected] (E.L.L.); [email protected] (N.K.); [email protected] (P.B.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: History suggests that tasteful properties of sugar have been domesticated as far back as 8000 BCE. With origins in New Guinea, the cultivation of sugar quickly spread over centuries of conquest and trade. The product, which quickly integrated into common foods and onto kitchen tables, is sucrose, which is made up of glucose and fructose dimers. While sugar is commonly associated with flavor, there is a myriad of biochemical properties that explain how sugars as biological molecules function in physiological contexts. Substantial research and reviews have been done on the role of glucose in disease. This review aims to describe the role of its isomers, fructose and mannose, in the context of inborn errors of metabolism and other metabolic diseases, such as cancer. While structurally similar, fructose and mannose give rise to very differing biochemical properties and understanding these differences will guide the development of more effective therapies for metabolic disease. We will discuss pathophysiology linked to perturbations in fructose and mannose metabolism, diagnostic tools, and treatment options of the diseases. Keywords: fructose and mannose; inborn errors of metabolism; cancer Citation: Lieu, E.L.; Kelekar, N.; Bhalla, P.; Kim, J. Fructose and Mannose in Inborn Errors of Metabolism and Cancer.
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]